Latest Content
Ebbs and flows in the infectious disease market
Medtech dealmaking and financing trends in 2017
Sponsor content
Collaborative Research and Licensing Opportunity: Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules
NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. The applications for this hybridoma include its use in immuno-fluorescence (IF) microscopy; DNA/RNA immunoprecipitation (DRIP) and also in diagnostic kits for viral/bacterial infections, cancers, and a variety of other human diseases. NIH researchers have also incorporated the antibody into a micro-array platform, expanding its potential for use in diagnostic devices.
Using BioPharma Dealmakers
All about how to get the most from the BioPharma Dealmakers website, whether you are a sponsoring Company or a Member.
Editorial content
Follow us on Twitter
BioPharma Dealmakers has just joined Twitter. Follow us for details of our latest content and partnering news stories.
Medtech dealmaking and financing trends in 2017
Diagnostics dealmaking in the past year
Medtech dealmaking and financing trends in 2016
CNS
The latest from BioPharma Dealmakers on companies, research and deals in the CNS field.
Drug Development
The latest from BioPharma Dealmakers on companies, research and deals in the drug development field.
Academic/Non-profit organisation
The latest from BioPharma Dealmakers on establishments, research and deals from academic and non-profit organisations.
Opening up academic partnerships
Oncology
The latest from BioPharma Dealmakers on companies, research and deals in the oncology field.
Gastrointestinal
The latest from BioPharma Dealmakers on companies, research and deals in the gastrointestinal field.
Dealmaking for inflammatory disorders
Dermatology
The latest from BioPharma Dealmakers on companies, research and deals in the dermatology field.
